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Mutations in glucokinase (GCK) cause a spectrum of glycemic disorders. Heterozygous loss-of-functionmuta-
tionscausemild fastinghyperglycemia irrespectiveofmutationseveritydue tocompensation fromtheunaffect-
ed allele. Conversely, homozygous loss-of-function mutations cause permanent neonatal diabetes requiring
lifelong insulin treatment. This study aimed to determine the relationship between in vitromutation severity
and clinical phenotype in a large international case series of patients with homozygous GCK mutations.
Clinical characteristics for 30 patients with diabetes due to homozygousGCKmutations (19 uniquemutations,
including 16 missense) were compiled and assigned a clinical severity grade (CSG) based on birth weight and
age at diagnosis. The majority (28 of 30) of subjects were diagnosed before 9 months, with the remaining two
at 9 and 15 years. These are the first two cases of a homozygous GCKmutation diagnosed outside infancy.
Recombinant mutant GCK proteins were analyzed for kinetic and thermostability characteristics and assigned
a relativeactivity index (RAI) or relativestability index (RSI) value. Sixof 16missensemutationsexhibitedsevere
kinetic defects (RAI ≤ 0.01). Therewas no correlation betweenCSGandRAI (r25 0.05,P 5 0.39), indicating that
kinetics alone did not explain the phenotype. Eighty percent of the remaining mutations showed reduced ther-
mostability, the exceptions being the two later-onset mutations which exhibited increased thermostability.
ComparisonofCSGwithRSIdetectedahighlysignificantcorrelation (r25 0.74,P 5 0.002).Wereport the largest
case series of homozygous GCKmutations to date and demonstrate that they can cause childhood-onset dia-
betes, with protein instability being the major determinant of mutation severity.
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INTRODUCTION
Homozygous mutations in the gene encoding the enzyme gluco-
kinase (GCK) cause a rare form of permanent neonatal diabetes
(PNDM; OMIM entry #606176) that requires lifelong insulin
treatment. Only 12 cases have been reported to date and all
were diagnosed within the first 9 months of life (1–7). Glucoki-
nase (GCK) acts as the pancreatic glucose sensor, and biallelic
inactivation severely compromises the ability of the pancreatic
b-cell to regulate insulin secretion in response to a glucose
challenge. Treatment with sulphonylureas has been shown to
augment insulin production in a single case report (4), but
there are no reports of patients with homozygousGCKmutations
who do not require insulin treatment. In contrast, heterozygous
inactivating GCK mutations are less deleterious and manifest
in a mild fasting hyperglycemia from birth (5.5–8 mmol l21)
otherwise known as maturity-onset diabetes of the young;
subtype GCK (GCK-MODY; OMIM entry #125851) (8).
Pharmacological treatment for these individuals is not usually
required (9).
Functional characterization has shown a broad range of
in vitro defects for.70 naturally occurring GCK-MODY muta-
tions, with a particular emphasis on kinetic effects (8). Protein
instability has also been shown to contribute to enzyme dysfunc-
tion in some cases via effects on enzyme turnover (10–20).
Individuals with heterozygous GCK mutations have a remark-
ably consistent phenotype due to compensation by the wild-type
(WT) allele, which is posttranslationally upregulated by glucose
(21). This means that the true relationship between in vitro
mutation severity and clinical phenotype can only be investi-
gated in patients with homozygous or compound heterozygous
GCK mutations.
In this study, we aimed to establish the molecular mechanisms
drivingGCK dysfunction through the evaluation of a large inter-
national case series of patients with homozygous GCK muta-
tions. We identified 19 unique mutations (16 missense, 2
frameshift, 1 deletion) in 30 patients: 28 patients with PNDM
and 2 with childhood-onset diabetes (diagnosed at age 9 and
15 years). These latter two individuals were referred for
genetic testing for MODY and are the first two reported patients
with a homozygous GCK mutation diagnosed outside infancy.
Combined with extensive clinical data, we were able to correlate
functional impact with clinical phenotype for the 16 missense
mutations by analyzing their effects on enzymatic activity and
thermostability in vitro. We discovered that protein instability
was more highly correlated with phenotypic severity than
kinetic dysfunction, providing the first corroborative evidence
that enzyme turnover may be a vital contributor to physiological
GCK mutational effects.
RESULTS
The cohort
We studied a cohort of 30 patients with 19 unique homozygous
GCK mutations (Table 1) (22). The mutations identified were
typically found in communities with high rates of consanguinity:
patients were mostly of Arabic, Turkish, Indian or Pakistani
ancestry. Twenty-eight of these patients have PNDM, and two
were diagnosed with diabetes aged 9 or 15 years, consistent
with MODY. All five individuals with the p.R397L mutation are
British Pakistanis, and the two individuals with childhood-onset
diabetes (i.e. the homozygous p.D160N and p.V226M carriers)
are white Canadians. Interestingly, in our cohort of GCK-
MODY individuals, over a quarter (12 of 46) of Canadian
probands have a heterozygous p.V226M GCK mutation, all of
whom are French Canadian (9). There is only one other proband
in our cohort (comprising.1200 individuals) with a heterozygous
p.V226M GCK mutation. Six of the 16 homozygous missense
mutations are novel (c.148C.G, p.H50D; c.491T.C, p.L146P;
c.451T.A, p.S151T; c.506A.G, p.K169R; c.1178T.C,
p.M393T; and c.1322C.T, p.S441L), as are the two duplication
mutations (c.764_767dup, p.E256fs and c.1121dup, p.S375fs)
and one deletion mutation (c.1256del, p.F419fs). The duplica-
tion/deletion mutations result in a premature termination codon
predicted to reduceprotein levelsandwerenot further investigated.
Four patients have previously been described [both patients with
a p.T168A mutation (4,7), one patient with a p.R397L mutation
(3) and the patient with a p.G261R mutation (6)].
Preliminary in silico analyses using the PolyPhen-2, SIFT and
Condel algorithms predicted all 16 missense mutations to be
damaging, with the exception of p.H50D and p.D160N, which
produced conflicting predictions (Supplementary Material,
Table S1) (23–25). We also mapped each missense mutation
onto the crystal structure of b-cell GCK and found that several
mutations were located within or proximal to the glucose and/
or adenosine triphosphate (ATP) binding sites (Fig. 1) (26).
Clinical features of neonatal diabetes patients
The majority (22 of 28) of patients with neonatal diabetes were
diagnosed within the first 3 months of life, with 10 diagnosed
within the first week. The median age of diagnosis was 21 days
(range 0–245 days). The median birth weight was 1700 g
(range 1250–3700 g) with 18 of the 28 patients having a birth
weight SDS below 22.0 (equivalent to the 1st centile). Three of
13 patients tested for fasting C-peptide showed signs of preserved
b-cell function, as defined by a cut-off score of ≥0.23 ng ml21
derived from the Diabetes Control and Complications Trial
(27). However, all patients required insulin treatment, with the
median dose being 1 unit kg21 day21 (range 0.7–1.3 units).
One previously reported patient was also treated with glibencla-
mide (4). Median HbA1c established on treatment for all 22
patients was 72 mmol mol21 [8.7%] (range 54–135 mmol
mol21 [7.1–14.5%]) (Table 1).
Clinical features of childhood-onset diabetes patients
The first patient was diagnosed with diabetes at 9 years of age.
She had asymptomatic, high fasting blood glucose readings for
3 years with mildly elevated postprandial glucose and was not
on pharmacological treatment. DNA was provided to investigate
the likelihood of a heterozygous GCK mutation but unexpectedly
revealed the presence of a homozygous mutation, c.478G.A,
p.D160N. This result was confirmed by Sanger sequencing using
alternative primers to check for allelic drop out. Analysis of par-
ental DNA confirmed that both parents were heterozygous
for the same mutation. Their fasting glucose levels were also
mildly elevated, consistent with a diagnosis of GCK-MODY
(Supplementary Material, Fig. S1A).
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Table 1. Clinical characteristics of patients with a homozygous GCK mutation
Mutation Cases BW (g) Gestational age
(weeks)
BW SDS Age at diagnosis
(days)
Glucose at diagnosis
(mmol l21)
C peptide
(ng ml21)
HbA1c (mmol
mol21 [%])
Insulin dose
(units kg21 day21)
Country
p.E40K
(c.118G.A)
1 1500 38 23.93 112 25 ,0.1 123 [13.4] 1.3 Pakistan
p.R43C (c.127C.T) 1 2300 37 21.50 161 23.1 N/A 79 [9.4] 1 India
p.H50D
(c.148C.G)
2 1425 (1250–
1600)
39 (38–39) 24.63
(24.41–24.85)
16 (3–28) 31 (23–39) 0.5 (0.1–0.9) 72 (54–89) [8.7
(7.1–10.3)]
1.1a Egypt
p.G72R
(c.214G.A)
1 2240 38 22.13 1 7.9 0.13 N/A 0.3 Turkey
p.L146P
(c.491T.C)
1 1465 35 22.53 1 24 0.11 69 [8.5] 0.8 Qatar
p.S151T
(c.451T.A)
1 1700 40 24.71 42 N/A N/A 64 [8.0] 1 India
p.D160N
(c.478G.A)
1 3285 N/Ac 20.16 3287 6.0 N/A 65 [8.1] None Canada
p.T168A
(c.502A.G)
2 1400a 37a 23.67a 151 (56–245) 17.3 (16.5–18.0) N/A 82 (63–100) [9.6
(7.9–11.3)]
1 (0.8–1.1) Turkey
p.K169R
(c.506A.G)
3 1750 (1600–
1900)
39 (38–40) 23.82
(23.67–23.94)
11 (1–28) 39.8 (28.0–48.0) 0.29 (0.08–
0.5)
63 (62–63) [7.9
(7.8–7.9)]a
1.4 (1.3–1.5)a Turkey
p.A208T
(c.623C.T)
2 1675 (1450–
1900)
38 (36–40) 23.4
(22.96–23.85)
18 (0–35) 26.7 (13.8–39.6) N/A 72 (69–74) [8.7
(8.5–8.9)]
1.2 (1.0–1.3) Poland
p.V226M
(c.676G.A)
1 3500 40 0.203 5479 N/A N/A N/A None Canada
p.E256fs
(c.764_767dup)
1 1600 38 23.75 21 N/A N/A N/A N/A India
p.G261R
(c.781G.A)
1 2400 39 22.22 7 20 N/A 89 [10.3] 1 Saudi Arabia
p.S375fs
(c.1121dup)
1 1500 36 22.92 140 20 ,0.10 135 [14.5] N/A Pakistan
p.M393T
(c.1178T.C)
1 2350 38 21.87 21 22.5 0.38 N/A 1 Turkey
p.R397L
(c.1190G.T)
5 1666 (1370–
1820)
37 (36–38) 23.08
(22.1–23.51)
24 (2–84) 21 (11–33)a N/A 83 (64–100) [9.7
(8.0–11.3)]a
1.1 (1.0–1.2)b UK/Pakistan
p.F419fs (c.1256del) 1 1400 36 23.17 14 18 N/A 89 [10.3] 1.3 Turkey
p.S441L
(c.1322C.T)
1 2500 38 21.53 84 17 N/A 83 [9.7] 1.3 Turkey
p.A449T
(c.1345G.A)
3 3233 (3000–
3700)
41 (40–42) 21.17
(21.92–0.32)
98 (21–126) 17.4 (13.8–22) 0.30 (0.05–
0.55)a
59 (54–64) [7.6
(7.1–8.0)]
0.9 (0.7–1.0) Jordan
Mutations are described according toHomo sapiensGCK reference sequence NM_000162.3. Where there is data for more than one patient per mutation, the mean and range are shown. The indicated range in BW
SDS refers to the range of birth weight for that mutation. BW, birth weight; SDS, standard deviation score; N/A, data not available.
aData unavailable for one individual.
bData unavailable for two individuals.
cPresumed ‘at term’ for calculation of BW SDS.
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The second patient was diagnosed with diabetes at 15 years of
age. She was treated with a basal-bolus insulin regime on the
basis of a presumed diagnosis of type 1 diabetes. However,
given a lack of GAD65/IA2 antibodies and a maternal family
history of diabetes for three generations (Supplementary Mater-
ial, Fig. S1B), she was referred for HNF1A and HNF4A genetic
testing. No mutation was found but further testing on a targeted
next-generation sequencing platform (28) revealed a homozy-
gous GCK mutation, c.676G.A, p.V226M.
Developing a clinical severity scoring system
To determine which clinical features could be used to define
severity of disease for this case series, we analyzed the linear
correlation for several clinical markers (HbA1c, insulin dose
day21 kg21, age at diagnosis, fasting C-peptide) against birth
weight standard deviation score (BW SDS) for all individuals.
We chose BW SDS as the reference variable for clinical severity
as it reflects insulin-mediated growth, which is dependent on
fetal insulin secretion in utero and is therefore a reliable, inde-
pendent indicator of GCK mutational severity. Only age at
diagnosis showed a significant linear correlation with BW SDS
(r2 ¼ 0.33, P ¼ 0.001) (Supplementary Material, Fig. S2). The
other factors either had insufficient clinical data for robust statis-
tical analysis (C-peptide, data not shown) or were haphazardly dis-
tributed [HbA1c (r2 ¼ 0.01, P ¼ 0.6), insulin dose day21 kg21
(r2¼ 0.16,P¼ 0.07)], perhaps indicative of variable concordance
with treatment or insufficient contact between patients and their
referring clinicians. We therefore assigned a clinical severity
score (CSS) to each patient based on degrees of BW SDS and
age at diagnosis, and used this information to allocate each
mutation to one of four graded categories according to their
cumulative score (Supplementary Material, Table S2).
Developing a functional severity scoring system
To establish whether there was any link between clinical severity
and in vitro enzyme characteristics, we performed functional
analysis on all 16 missense mutations using the previously char-
acterized neutral rare variants p.G68D and p.T342P as controls
for WT-like activity (29,30). Fourteen missense mutations dis-
played inactivating kinetics, including four mutations that
retained ,10% activity (relative activity index, RAI, 0.1)
relative to WT-GCK, and six mutations that were so kinetically
deficient that they retained 1% activity or less (RAI ≤ 0.01)
(Supplementary Material, Table S3). The remaining mutations
displayed minimal loss of activity, and in the case of p.A449T
was paradoxically mildly kinetically activating. The two
childhood-onset mutations (p.D160N and p.V226M) were
among those that retained ,10% WT activity. There was no
linear correlation between RAI and clinical severity grade
(CSG) (r2 ¼ 0.05,P ¼ 0.39), demonstrating that kinetic charac-
teristics alone were insufficient to explain the PNDM phenotype
(Fig. 2A).
Given the lack of correlation with kinetic characteristics, we
explored other mechanisms of enzyme dysfunction, and inves-
tigated the behavior of every mutant GCK protein that dis-
played .1% activity relative to WT-GCK (RAI . 0.01; a
total of 10 mutants) in thermostability assays. Thermal instabil-
ity has been shown to be indicative of reduced cellular GCK
protein expression (11,20). Across a temperature range of
40–638C, WT, p.G68D and p.T342P-GCK retained at least
100% activity up to 51.88C, after which their activity
dropped dramatically due to thermal denaturation (Fig. 3A).
Eight of 10 mutants displayed markedly inferior thermostabil-
ity characteristics, as indicated by loss of activity at much lower
temperatures (Fig. 3A). The behavior of these eight proteins
could be accurately captured by logistic regression models,
and examination of the residual plot for each protein confirmed
the appropriateness of this approach, as we observed an excel-
lent match (i.e. small, randomly distributed differences only)
between the observed activities at each temperature point and
those predicted by the fitted models (Fig. 3B). For WT,
p.G68D and p.T342P-GCK, however, systematic differences
were seen between the observed and predicted activities,
mainly due to an increase in activity for these proteins up to
51.88C (Fig. 3A and B). This increase was also seen for the
two childhood-onset mutations (p.D160N and p.V226M) but
to a much greater extent, resulting in significantly higher activ-
ities for these two mutants at 51.88C compared with WT (P ,
0.001 for both proteins, Student’s t-test). These results suggest
that the p.D160N and p.V226M substitutions confer an atypical
stability profile to the GCK protein that may be indicative of
enhanced cellular stability in vivo.
We assigned each mutant a relative stability index (RSI)
value, which was calculated from the temperature point at
which each mutant protein displayed 50% activity (TA50) (Sup-
plementary Material, Table S3). Even though this approach did
not take into account the greater activity maxima for the
p.D160N and p.V226M proteins compared with WT, there was
a highly significant linear correlation between CSG and RSI
(r2 ¼ 0.74, P ¼ 0.002) (Fig. 2B), indicating that increased clin-
ical (and hence mutational) severity is related to the underlying
degree of protein instability in this dataset.
Figure 1. Ribbon model of the closed (glucose-bound) form of human GCK
illustrating each of the 16 missense mutations. Glucose is indicated in stick
form in the center of the active site.
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DISCUSSION
Here, we report a series of 30 patients with 19 unique homozy-
gous GCK mutations, including the first two cases of a homozy-
gous mutation diagnosed with diabetes outside infancy (aged 9
and 15 years). This study significantly extends the phenotypic
spectrum of naturally occurring homozygous GCK mutations,
and utilizes both clinical and in vitro approaches to provide the
first systematic investigation of genotype–phenotype correla-
tions within a large group of patients with homozygous GCK
mutations. We demonstrate that these mutations commonly
affect GCK by altering enzyme stability as well as kinetics,
and that a significant correlation with phenotypic severity was
only revealed when both were considered. This was particularly
the case for the childhood-onset p.D160N and p.V226M muta-
tions, which displayed inactivating kinetics indistinguishable
from the neonatal-onset mutations, but thermostability charac-
teristics indicative of ‘super-stable’ proteins, thereby suggesting
that improved protein stability may ameliorate disease severity
by increasing the available pool of GCK protein. Further
studies will be needed to characterize the cellular phenotype of
these proteins more fully.
Figure 2. Linear regression analysis of Clinical Severity Grade against (A) RAI or (B) RSI for GCK missense mutations. The 95% confidence intervals for the linear
regression lines are shaded in gray.
Figure 3.Assessment of thermostability for WT and mutant human GST-GCK proteins. Logistic regression modelling was used to fit an activity curve to each protein
in (A). Data were normalized to the baseline level of activity for each protein at 408C. Each point represents mean activity+SEM (n ¼ 3 experiments except for WT
and p.T342P n ¼ 10 and p.D160N n ¼ 6). The raw residuals, defined as the difference between observed and predicted values, for all proteins are shown in (B).
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Our study brings the total number of homozygous GCK cases
described worldwide to 38 (1–7). The clinical phenotype of the
GCK-PNDM individuals in our case series is similar to that
observed in the literature to date: very low birth weight, typically
,2.5th centile; diagnosis of diabetes within the first few months
of life; and insulin treatment required. The childhood-onset
c.478G.A, p.D160N mutation has been reported in the heterozy-
gous state in six other cases of GCK-MODY and co-segregated
with raised fasting glucose in these families (8). Similarly, the
c.676G.A, p.V226M mutation has also been previously reported
in 12 families where a heterozygous mutation co-segregated with
raised fasting glucose in a manner consistent with GCK-MODY in
at least two generations (8).
The unexpected functional results of this study suggest that
protein stability should be more rigorously explored as a key
mechanism of GCK inactivation. This has been previously pro-
posed for some naturally occurring GCK-MODY mutations
(10–19,21,31), including a few that have also been studied in
mice (20,32), but has never been systematically investigated in
such a large group of patients with homozygous GCK mutations.
Furthermore, our results indicate that protein stability may be
the principal determinant of phenotypic severity for all but the
most severely kinetically defective mutations. We identified six
mutations (p.L146P, p.S151T, p.T168A, p.K169R, p.A208T and
p.G261R) with negligible activity in kinetic assays, four of
whichmapdirectly to theglucosebindingsiteofGCK(Fig.1;Sup-
plementary Material, Table S3). It is reasonable to predict that
these mutations would be essentially unresponsive to glucose in
a cellular context and could therefore be considered ‘null’ muta-
tions solely on the basis of their kinetic characteristics, although
it is possible that they may also be thermolabile (11). Individuals
with these mutations possessed among the highest CSSs, suggest-
ing that they may indeed retain minimal GCK functionality
(Supplementary Material, Table S2). Our statistical analyses,
however, indicated that the overall severity of the remaining muta-
tions was more readily explained by their thermostability charac-
teristics, suggesting that the cell may be relatively tolerant to loss
of GCK function provided that a sufficient ‘steady state’ pool of
readily accessible enzyme is maintained. Studies in homozygous
or compound heterozygous Gck mutant mice have also found a
correlation between severity of hyperglycemia and protein stabil-
ity via thermal shift experiments, pointing towards a key role for
enzyme turnover in determining disease severity (20,32).
In summary, we present the largest case series of homozygous
GCK mutations reported to date, and demonstrate for the first
time that clinical presentation of diabetes is determined by
in vitro mutation severity, with milder mutations causing
childhood-onset diabetes. Homozygous GCK mutations are
thus a rare cause of childhood-onset diabetes and could be con-
sidered in consanguineous or isolated populations. Furthermore,
we demonstrate that the major determinant of mutation severity,
except in cases where a mutation completely abolishes kinetic
activity, is protein instability.
MATERIALS ANDMETHODS
Study subjects
We collated clinical details for 30 patients with diabetes due
to homozygous GCK mutations. The two childhood-onset
cases were identified through diagnostic genetic testing for
MODY. Parent and family details are routinely collected
as part of the neonatal diabetes service to facilitate an appro-
priate testing strategy. Where there were missing family
details, we contacted the referring clinicians to request add-
itional information.
GCK screening and mutation identification
We screened the b-cell isoform of GCK (NM_000162.3) in 22
patients with neonatal diabetes by Sanger sequencing in consan-
guineous pedigrees. A further six cases of genetically undiag-
nosed neonatal diabetes were screened on the Illumina
HiSeq2000 targeted next-generation sequencing platform cov-
ering all known monogenic diabetes genes (28). One of the
two patients with childhood-onset diabetes was diagnosed by
Sanger sequencing during routine genetic testing and the other
by next-generation sequencing as described above. All identified
sequence variants were submitted to the Leiden Oven Variant
Database for GCK (www.lovd.nl/GCK, last accessed on 19
May 2014).
Clinical and laboratory analyses
Patients’ clinicians were contacted by email to identify clinical
details including birth weight, gestational age, age at diabetes
diagnosis, HbA1c, glucose at diagnosis, C-peptide with matched
glucose, current treatment and insulin dose corrected for weight
and ethnicity. Clinical details for each of the patients’ mutations
are given in Table 1.
A CSS for each patient was subsequently calculated based on
degrees of BW SDS and age at diagnosis (Supplementary Mater-
ial, Table S2). BW SDS, according to World Health Organization
guidelines (http://www.rcpch.ac.uk/growthcharts, last accessed
on 24 March 2014), was first divided into quartiles. Patients in
the highest birth weight quartile scored 1, whereas those in the
lowest quartile scored 4. Age at diagnosis was scored such that
diagnosis within 1 week scored 4, within 1 month scored 3,
within 6 months scored 2 and the remainder scored 1. The cumu-
lativeCSS for each patientwas the sum of their BWSDS scoreand
their age at diagnosis score, with a maximum possible total score
of 8. Where more than one patient was identified with the same
GCK mutation, individual CSSs were averaged by mutation to
give a mutation-specific CSS.
A CSG was assigned to each mutation according to its CSS.
The maximum possible total score was first divided into four
grades. Those with CSS, 2 were designated ‘Very Mild’, those
with 2, CSS ≤ 4 were designated ‘Mild’, those with 4,
CSS ≤ 6 were designated ‘Moderate’ and those with CSS. 6
were designated ‘Severe’.
Cloning and mutagenesis
Mutations were introduced into the b-cell GCK variant (17) via
site-directed mutagenesis using the Stratagene QuikChange II
kit (Agilent Biotechnologies) according to the manufacturer’s
instructions. All plasmid sequences were verified by sequencing.
All primers were obtained from Eurofins Genetic Services Ltd
Primer sequences are available upon request.
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Protein production
Production of GST-tagged WT and mutant GCK proteins has
been described previously (17,33).
Functional characterization
GCK activity was measured spectrophotometrically using
glucose 6-phosphate dehydrogenase-coupled assays essentially
as described (16,17). Affinity for glucose was measured in the
presence of 0–100 mmol l21 glucose, except for the particularly
deleterious mutants p.E40K and p.H50D where it was increased
to 0–200 mmol l21; p.V226M 0–500 mmol l21; and p.T168A,
p.A208T and p.G261R 0–1000 mmol l21. Affinity for ATP was
determined in the presence of 0–5 mmol l21 ATP, except for the
particularly deleterious mutants p.G72R and p.A449T where it
was increased to 0–10 mmol l21; p.T168A and p.V226M 0–
25 mmol l21; and p.A208T 0–20 mmol l21.
Thermostability assays were conducted essentially as
described (16, 18). Each variant was analyzed over a 12-point
temperature gradient spanning 40–638C. All variants were ana-
lyzed at a final glucose concentration of 8 mmol l21 except for
the p.E40K and p.H50D variants, which were analyzed at
22 mmol l21 glucose, and the p.V226M variant, which was ana-
lyzed at 45 mmol l21 glucose. WT-GCK and the control variant
p.T342P-GCK were analyzed at all glucose concentrations. The
thermostability characteristics of these proteins did not alter in
response to glucose concentration.
Graphical and statistical analyses
Glucose affinity (S0.5), Hill number (nH) and turnover number
(Kcat) values were calculated using the Hill equation. ATP affin-
ity (ATPKm) was calculated using the Michaelis–Menten equa-
tion. All data fits were performed using Kaleidagraph v3.52
(Synergy Software). Relative activity indices were calculated
using the equation first described by Christesen et al., which nor-
malizes to a blood glucose of 5 mmol l21 (Kcat values were taken
from the glucose S0.5 assay) (34). Relative stability indices
were defined as (TA50(mutant) 2 TA50(min))/(TA50(WT) 2
TA50(min)), where TA50 refers to the temperature point at
which each protein displayed 50% of its activity at 408C and
TA50(min) refers to the minimum observed TA50 of any con-
struct in this assay.
For comparison of clinical markers with BW SDS, linear cor-
relation analyses were conducted using Stata 13.1. The relation-
ship between CSG and RAI or RSI was analyzed via linear
regression in R 3.0.2. All other clinical data analyses—including
calculation of medians and quartiles of BW SDS—were performed
using Stata 13.1. For thermostability assays, a five-parameter
logistic regression model was used to fit thermostability data
and calculate raw residuals and TA50 values for each mutant
in R 3.0.2.
Bioinformatic analyses
Predicted pathogenicity for all variants was assessed using the
PolyPhen v.2.2.2, SIFT Human Protein, and Condel web
server algorithms (23–25).
Structural modelling
Variants were mapped onto the crystal structure of human GCK
bound to glucose (closed form; Protein DataBank entry 1V4S)
using PyMOL v.0.99.
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